** Shares of medical device maker Dexcom DXCM.O rise 8.6% to $72.60 premarket
** Co says U.S. FDA has cleared its 15-day continuous glucose monitoring (CGM) device called Dexcom G7 15 Day for people over the age of 18 with diabetes in the United States
** Co says the CGM lasts for 15.5 days and helps in "easier glucose management with fewer monthly sensors and reduced monthly waste"
** Co's other G7 CGM lasts for up to 10 days, while its over-the-counter CGM Stelo also lasts for 15 days
** Approval for co's 15-day CGM should provide momentum through 2025, brokerage William Blair had said in a note in February
** Up to last close, stock had fallen 14.1% YTD
(Reporting by Sneha S K )
(( Sneha.SK@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。